Zealand Pharma initiated with an Overweight at JPMorgan
The Fly

Zealand Pharma initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Zealand Pharma (ZLDPF) with an Overweight rating and DKK 1,100 price target The firm cites the company’s obesity pipeline strength, in particular long acting Amylin, with likely partnering validation in 2025, for the bullish rating.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App